📇 Rhumatologue · PARIS CEDEX 14 · (75) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
16 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
43
43 articles ont été cités au moins 43fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
5 894
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
292
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
102
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre National de la Recherche Scientifique · Inserm · Inserm
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Beyond overweight, visceral adiposity is associated with estimation of cardiovascular risk in patients living with type 1 diabetes: findings from the SFDT1 cohort
2025ArticleCardiovascular Diabetology
Screening for autoimmune atrophic gastritis by serum gastrin measurement in subjects with type 1 diabetes
2025ArticleDiabetes & Metabolism
PFMG2025–integrating genomic medicine into the national healthcare system in France
2025ArticleThe Lancet Regional Health - Europe
ACBP/DBI neutralization for the experimental treatment of fatty liver disease
2024ArticleCell Death and Differentiation
Heterogeneity of glycaemic phenotypes in type 1 diabetes
2024ArticleDiabetologia
Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort
2024ArticleClinical Diabetes and Endocrinology
Pancreatic enzyme replacement therapy in subjects with exocrine pancreatic insufficiency and diabetes mellitus: a real-life, case–control study
2024ArticleDiabetology and Metabolic Syndrome
Protein supplementation changes gut microbial diversity and derived metabolites in subjects with type 2 diabetes
2023ArticleiScience
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP CUP SITE COCHIN PORT ROYAL
27 R DU FAUBOURG SAINT JACQUES, 75679 PARIS CEDEX 14
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Diabetologia · 2021
Abstract Aims/hypothesis This is an update of the results from the previous report of the CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes) study, which aims to describe the outcomes and prognostic factors in patients with diabetes hospitalised for coronavirus disease-2019 (COVID-19). Methods The CORONADO initiative is a French nationwide multicentre study of patients with diabetes hospitalised for COVID-19 with a 28-day follow-up. The patients were screened after hospital admission from 10 March to 10 April 2020. We mainly focused on hospital discharge and death within 28 days. Results We included 2796 participants: 63.7% men, mean age 69.7 ± 13.2 years, median BMI (25th–75th percentile) 28.4 (25.0–32.4) kg/m2. Microvascular and macrovascular diabetic complications were found in 44.2% and 38.6% of participants, respectively. Within 28 days, 1404 (50.2%; 95% CI 48.3%, 52.1%) were discharged from hospital with a median duration of hospital stay of 9 (5–14) days, while 577 participants died (20.6%; 95% CI 19.2%, 22.2%). In multivariable models, younger age, routine metformin therapy and longer symptom duration on admission were positively associated with discharge. History of microvascular complications, anticoagulant routine therapy, dyspnoea on admission, and higher aspartate aminotransferase, white cell count and C-reactive protein levels were associated with a reduced chance of discharge. Factors associated with death within 28 days mirrored those associated with discharge, and also included routine treatment by insulin and statin as deleterious factors. Conclusions/interpretation In patients with diabetes hospitalised for COVID-19, we established prognostic factors for hospital discharge and death that could help clinicians in this pandemic period. Trial registration Clinicaltrials.gov identifier: NCT04324736 Graphical abstract
Diabetes care · 2023
OBJECTIVEMost people with type 2 diabetes (T2DM) and nonalcoholic steatohepatitis (NASH) or advanced fibrosis (AF) remain undiagnosed, resulting in missed opportunities for early intervention. This multicenter, prospective study assessed the yield of using routinely available data to identify these patients.RESEARCH DESIGN AND METHODSA total of 713 outpatients with T2DM, screened in four diabetology clinics for nonalcoholic fatty liver disease according to American Diabetes Association criteria, were referred to hepatologists for further work-up (Fibrosis-4 and vibration-controlled transient elastography [VCTE]). A liver biopsy was proposed when ALT levels were persistently >20 IU/L in female patients or >30 IU/L in male patients, in the absence of other liver disease.RESULTSLiver biopsies were performed in 360 patients and considered adequate for reading after central review for 330 specimens (median patient age, 59 years; male patients, 63%; median BMI and HbA1c values, 32 and 7.5%, respectively). Prevalence of NASH, AF, and cirrhosis were 58%, 38%, and 10%, respectively. Liver lesions were independently associated with the components of metabolic syndrome but not with the micro- and macrovascular complications of T2DM. Models based on routinely available data with or without VCTE had good accuracy to predict AF (respectively: area under the receiver operating characteristic curve [AUROC], 0.84 and 0.77; and correctly classified 59% and 45%) and NASH (respectively: AUROC, 0.82 and 0.81; 44% and 42%).CONCLUSIONSDespite the use of a low ALT threshold, prevalence of NASH (58%) or AF (38%) was high. Routinely available data had a high yield in identifying patients with T2DM with AF and/or NASH requiring further liver assessment.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2021
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Diabetic medicine : a journal of the British Diabetic Association · 2026 · Journal Article
Metghalchi S, Bonnet-Serrano F, Alexandre L, Daclin S, et al.
Clinical diabetes and endocrinology · 2024 · Journal Article
Ossima AN, Brzustowski A, Paradis V, Van Beers B, et al.
Diabetology & metabolic syndrome · 2024 · Journal Article
Alexandre-Heymann L, Yaker F, Lassen PB, Dubois-Laforgue D, et al.
Diabetologia · 2022 · Journal Article
Sola-Gazagnes A, Pecquet C, Berré S, Achenbach P, et al.
Clinics and research in hepatology and gastroenterology · 2022 · Journal Article
Stempak-Droissart T, Rousset-Jablonski C, Spritzer PM, Lalhou N, et al.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2021 · Comparative Study
Hansel B, Potier L, Chalopin S, Larger E, et al.
Diabetologia · 2021 · Journal Article
Wargny M, Potier L, Gourdy P, Pichelin M, et al.
Medecine sciences : M/S · 2021 · Journal Article
Larger É
Diabetes care · 2023 · Multicenter Study
Castera L, Laouenan C, Vallet-Pichard A, Vidal-Trécan T, et al.
Diabetes technology & therapeutics · 2023 · Multicenter Study
Diedisheim M, Pecquet C, Julla JB, Carlier A, et al.
Cardiovascular diabetology · 2025 · Journal Article
Salle L, Julla JB, Fagherazzi G, Gourdy P, et al.
Diabetes & metabolism · 2022 · Journal Article
Riveline JP, Vergés B, Detournay B, Picard S, et al.
Diabetes & metabolism · 2023 · Case Reports
Daclin S, Ramos N, Larger E
Diabetes & metabolism · 2023 · Randomized Controlled Trial
Thivolet C, Larger E, Cariou B, Renard E, et al.
Diabetes, obesity & metabolism · 2025 · Journal Article
Vermillac G, Lafont C, Godot C, Kerbourc'h S, et al.
Association of environmental markers with childhood type 1 diabetes mellitus revealed by a long questionnaire on early life exposures and lifestyle in a case–control study
Abstract Background The incidence of childhood type 1 diabetes (T1D) incidence is rising in many countries, supposedly because of changing environmental factors, which are yet largely unknown. The purpose of the study wa
Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort
Abstract Background & aims Despite its high prevalence in the western world metabolic dysfunction-associated steatotic liver disease (MASLD) does not benefit from targeted pharmacological therapy. We measured healthc
Insulitis and exocrinitis in autoantibody-positive non-diabetic individuals nPOD donors: individual characteristics
The clinical characteristics of the 30 organ donors with available virtual slides who were included in the present study are individually detailed in Supplementary Table 1, for the article "Low prevalence of high-risk HL
Performance of intermittently scanned continuous glucose monitoring systems in people with type 1 diabetes: A pooled analysis
Aims To conduct a pooled analysis to assess the performance of intermittently scanned continuous glucose monitoring (isCGM) in association with the rate of change in sensor glucose in a cohort of children, adolescents, a
Additional file 2: of Association of environmental markers with childhood type 1 diabetes mellitus revealed by a long questionnaire on early life exposures and lifestyle in a case–control study
The results of matched analysis and propensity analysis including questionnaire section, question description, labels used in figures, missing data separately for cases and controls, p-values, effect size ad confidence i
Additional file 4: of Association of environmental markers with childhood type 1 diabetes mellitus revealed by a long questionnaire on early life exposures and lifestyle in a case–control study
Results of the analysis described in Additional file 3. (XLS 12 kb)
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Cardiovascular and interventional radiology · 2021 · Journal Article
Del Giudice C, Galloula A, Tiercelin C, Vilfaillot A, et al.